Walleye Trading’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-4,300
Closed -$253K 5633
2023
Q4
$253K Sell
4,300
-900
-17% -$50.6K ﹤0.01% 3625
2023
Q3
$227K Buy
5,200
+900
+21% +$32.1K ﹤0.01% 3525
2023
Q2
$155K Buy
4,300
+2,000
+87% +$82.4K ﹤0.01% 3552
2023
Q1
$85.5K Buy
+2,300
New +$103K ﹤0.01% 3909
2022
Q4
Sell
-14,700
Closed -$1.03M 5549
2022
Q3
$1.03M Sell
14,700
-32,500
-69% -$2.4M ﹤0.01% 2233
2022
Q2
$3.17M Buy
47,200
+39,200
+490% +$2.49M 0.01% 1314
2022
Q1
$658K Sell
8,000
-500
-6% -$51.1K ﹤0.01% 2632
2021
Q4
$1.25M Buy
8,500
+4,100
+93% +$637K ﹤0.01% 2034
2021
Q3
$778K Buy
+4,400
New +$708K ﹤0.01% 2480
2021
Q1
Sell
-5,500
Closed -$1.21M 5444
2020
Q4
$1.21M Buy
+5,500
New +$1.19M 0.01% 1813
2020
Q2
Sell
-8,700
Closed -$669K 4717
2020
Q1
$669K Buy
+8,700
New +$780K 0.01% 1619
2019
Q3
Sell
-63,700
Closed -$6.56M 4531
2019
Q2
$6.56M Buy
63,700
+43,700
+219% +$3.4M 0.06% 330
2019
Q1
$1.47M Buy
20,000
+15,100
+308% +$1.03M 0.01% 1325
2018
Q4
$208K Buy
+4,900
New +$195K ﹤0.01% 3363

Other funds holding MRTX

Walleye Trading's MRTX Position: Q1 2024 in Review

Walleye Trading sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 2,425 shares — an estimated $142K sold.

Walleye Trading first reported a position in MRTX in Q3 2016 and held it in 7 quarters. The position peaked at $1.09M in Q4 2019. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Walleye Trading reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Walleye Trading sold 2,425 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $142K.
  • Walleye Trading first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2016 and held it in 7 quarters.
  • Walleye Trading's Mirati Therapeutics, Inc. Common Stock position peaked at $1.09M in Q4 2019.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Walleye Trading's 13F filing for Q1 2024, filed 15 May 2024.